Isaac Livshetz, MD
Adult Reconstructive Orthopaedic Surgery · White Plains, NYNPI 1427391754
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,181 of the $11,547 with a category attached, or 70.9%. 12 manufacturers reported payments, led by Stryker at 58.7% of the total. Reporting peaked in 2019 at $4,137 and has fallen 55.2% since, to $1,854 in 2025. That places this record below the midpoint for adult reconstructive orthopaedic surgery clinicians in NY, where the typical reported total is $11,547.
Across 141 payments — averaging $81.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$7K
- Medical Device Business Services, Inc.$2K
- Johnson & Johnson$1K
- Bioventus LLC$421
- Smith+Nephew$358
- Zimmer Biomet$349
- plus $555 from 6 others
What the payments were for
- Travel & lodging$3,36629%
- Food & beverage$8,18171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 96 | $6,781 |
| Medical Device Business Services, Inc. | 16 | $1,817 |
| Johnson & Johnson | 12 | $1,266 |
| Bioventus LLC | 3 | $421 |
| Smith+Nephew | 3 | $358 |
| Zimmer Biomet | 3 | $349 |
| Gotham Surgical Solutions & Devices, Inc. | 3 | $224 |
| Nevro Corp. | 1 | $138 |
| Arthrex | 1 | $125 |
| AbbVie | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$3,002
- ACTIS$1,401
- ATTUNE$1,401
- ACCOLADE$853
- TRIATHLON$755
- Durolane$284
- ADAPT$268
- MONOVISC$246
- T-Fix$170
- Journey II BCS$170
- PICO 7 Single Use Negative Pressure Wound Therapy$170
- REDAPT Revision Hip System$170
- ALLOFIBER$161
- AXSOS$152
- Bioinductive Implant with Arthroscopic Delivery System - Medium$149
- Omnia$138
- XCELL$137
- Persona$134
- TRITANIUM$121
- ABSOLUTE$120
How this compares
$11,547 in reported general payments places this provider in the 50th percentile of 85 adult reconstructive orthopaedic surgery providers in New York.
See all adult reconstructive orthopaedic surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 20 | $643 |
| Meloxicam | 38 | $148 |
| Methylprednisolone | 12 | $79 |
Paid to pharmacies, not to this prescriber.
Other adult reconstructive orthopaedic surgery in White Plains
- Seth JerabekNew York$7.1M
- Jose RodriguezNew York$3.4M
- Friedrich BoettnerNew York$2.9M
- Jonathan VigdorchikNew York$2.3M
- William LongNew York$1.5M
- Peter SculcoNew York$1.5M
- Roshan ShahNew York$1.3M
- Herbert CooperNew York$1.3M
- Matthew AustinNew York$986K
- Patrick MeereNew York$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.